The expression of DNA damage checkpoint proteins and prognostic implication in metastatic brain tumors

Oncology Research

Volumn 19, Issue 8-9, 2011, Pages 381-390

  Seol, Ho Jun ^a   Yoo, Hae Yong ^b   Jin, Juyoun ^a,b   Joo, Kyeung Min ^a,b,c   Kim, Hyeong Seok ^a,b   Yoon, Su Jin ^b   Choi, Seung Ho ^b   Kim, Yonghyun ^a,b   Pyo, Hong Ryull ^a   Lim, Do Hoon ^a   Kim, Wook ^d   Um, Hong Duck ^e   Kim, Jong Hyun ^a   Lee, Jung Il ^a   Nam, Do Hyun ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Korea University   (South Korea)

^e Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

DNA damage checkpoint; Metastatic brain tumor; Phosphorylated Chk1 (P Chk1); Radioresistance; TopBP1

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DNA DAMAGE CHECKPOINT; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; DNA DAMAGE; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION;

EID: 84255162117     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X13123323849654     Document Type: Article

References (20)

1. Patchell, R. A. The management of brain metastases. Cancer Treat. Rev. 29:533-540; 2003.
2. Choi, J. H.; Sancar, A.; Lindsey-Boltz, L. A. The human ATR-mediated DNA damage checkpoint in a reconstituted system. Methods 48:3-7; 2009.
3. Sancar, A.; Lindsey-Boltz, L. A.; Unsal-Kacmaz, K.; Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73:39-85; 2004.
4. Cuadrado, M.; Martinez-Pastor, B.; Murga, M.; Toledo, L. I.; Gutierrez-Martinez, P.; Lopez, E.; Fernandez-Captillo, O. ATM regulates ATR chromatin loading in response to DNA double-strand breaks. J. Exp. Med. 203: 297-303; 2006.
5. Myers, J. S.; Corlez, D. Rapid activation of ATR by icnizing radiation requires ATM and Mre11. J. Biol. Chem. 281:9346-9350; 2006.
6. Shibata, A.; Barton, O.; Noon, A. T.; Dahm, K.; Deckbar, D.; Goodarzi, A. A; Lobrich, M.; Jeggo, P. A. The role of ATM and the damage response mediatcr proteins, 53BP1 and MDC1, in the maintenance of G2/M checkpoint arrest. Mol. Cell. Biol. 30:3371-3383; 2010.
7. Kumagai, A.; Lee, J.; Yoo, H. Y.; Dunphy, W. G. TopBP1 activates the ATR-ATRIP complex. Cell 124:943-955; 2006.
8. Yoo, H. Y.; Kmnagi, A; Shevchenko, A; Dunphy, W. G. The Mrell-RadSO-Nbsl complex mediates activation of TopBP1 by ATM. Mol. Biol. Cell 20:2351-2360; 2009.
9. Shiloh, Y. Ataxia-telangiectasia and the Nijntgen breakage sdrome: Related disorders but genes apart. Annu. Rev. Genet. 31:635-662; 1997.
10. Choudhwy, A.; Cuddihy, A.; Bristow, R. G. Radiation and new molecular agents part I: Targeting ATM-ATR checkpoints, DNA repair, and the proleasome. Semin. Radiat. Oncol. 16:51-58; 2006.
11. Eastman, A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J. Cell Biochem. 91: 223-231; 2004.
12. Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15:2177-2196; 2001.
13. Kastan, M. B.; Bartek, J. Cell-cycle checkpoints and cancer. Nature 432:316-323; 2004.
14. Yoo, H. Y.; Kumagai, A.; Shevchenko, A.; Shevchenko, A.; Dunphy, W. G. Ataxia-telangiectasia mutated (ATM)-dependent activation of ATR ctzurs through phosphorylation of TopBP1 ty ATM. J. Biol. Chem. 282:17501-17506; 2007.
15. Das, A. K; Sato, M.; Story, M. D.; Peyton, M.; Graves, R.; Redpath, S.; Girard, L.; Oazdar, A. F.; Shay, J. W.; Minna, J. D.; Nircil, C. S. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor recefor are sensitive to ionizing radiation. Cancer Res. 66:9601-9608; 2006.
16. Zhao, J.; Li, Q. Q.; Zou, B.; Wang, G.; Li, X.; Kim, J. E.; Cuff, C. F.; Huang, L.; Reed, E.; Oarther, K. In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma. Tnt. J. Oncol. 31:241-252; 2007.
17. Zeng, L.; Kizaka-Kondoh, S.; Itasaka, S.; Xie, X.; Tnoue, M.; Tanimoto, K.; Shibuya, K.; Hirka, M. Hypoxia inducible factor-i influences sensitity to pacitaxel of human lung cancer cell lines undr normoxic conditions. Cancer Sci. 98:1394-1401; 2007.
18. Ono, Y.; Tamiya, T.; Icliikawa, T.; Matsunflo, K; Fumta, T.; Ohmoto, T.; Akiyama, K; Seki, S.; Ueki, K.; Louis, D. N. Accumulation of wild-type p53 in astrccytomas is asscciated th increased p21 expression. Acta Neuropathol. 94:21-27; 1997.
19. Faria, M. H.; Patrocinio, R. M.; Moraes Filho, M. O.; Rabenhorst, S. H. Immunoxpression of tumor suppressor genes p53, p21 WAF1/CIP1 and p77 KIP1 in humam astrocystic tumors. Arq. Neuropsiquiatr. 65:1114-1122; 2007.
20. Yang, H.; Yoon, S. J.; Jin, J.; Choi, S. H.; Seol, H. J.; Lee, J. I.; Nam, D. H.; Yoo, H. Y. Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy. Biochem. Biophys. Res. Commun. 406:53-58; 2011.